{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) have been linked to the most common familial form and some sporadic forms of Parkinson's disease (PD)... leading to the hypothesis of 'gain-of-function' in LRRK2 mutants with enhanced kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a 'gain-of-function' in LRRK2 mutants associated with PD, involving altered kinase and GTPase activities that contribute to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We examined the pS935 levels in the PD-linked mutants of LRRK2 expressed in HEK-293T cells... and 14-3-3 binding with LRRK2 variants in transfected cells.",
          "judgment": "Yes",
          "reasoning": "The assays used (phosphorylation level assessment via Western blot and protein binding via co-immunoprecipitation) are relevant to model the disease mechanism of altered kinase activity and protein interactions in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C isolated from cells have markedly reduced pS935 levels... Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type LRRK2 as a normal control and reports data from multiple replicates (three independent experiments), satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, all three mutants (S935A, R1441G, and G2019S) exhibited reduced co-immunoprecipitation with Myc-14-3-3c... R1441G mutant from transgenic brain again exhibited a marked reduction of pS935 levels.",
          "judgment": "Yes",
          "reasoning": "The study includes other known PD-linked variants (e.g., G2019S, Y1699C) as controls alongside R1441G, which are recognized as pathogenic in the field, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data was analyzed by One-way ANOVA (** P<0.01). Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) is performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood for functional data specific to R1441G.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C... and G2019S... were tested for pS935 levels and 14-3-3 binding.",
          "judgment": "Less than 11 controls",
          "reasoning": "The study includes fewer than 11 total benign/pathogenic variant controls (only a few mutants like G2019S and Y1699C are mentioned alongside wild-type), limiting the strength of evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441G is rated as PS3_supporting due to reduced phosphorylation at S935 and impaired 14-3-3 binding, which align with a pathogenic mechanism in PD. However, the limited number of variant controls and lack of OddsPath calculation restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) have been linked to the most common familial form and some sporadic forms of Parkinson's disease (PD)... leading to the hypothesis of 'gain-of-function' in LRRK2 mutants with enhanced kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a 'gain-of-function' in LRRK2 mutants associated with PD, involving altered kinase and GTPase activities that contribute to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We examined the pS935 levels in the PD-linked mutants of LRRK2 expressed in HEK-293T cells... and 14-3-3 binding with LRRK2 variants in transfected cells.",
          "judgment": "Yes",
          "reasoning": "The assays used (phosphorylation level assessment via Western blot and protein binding via co-immunoprecipitation) are relevant to model the disease mechanism of altered kinase activity and protein interactions in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C isolated from cells have markedly reduced pS935 levels... Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type LRRK2 as a normal control and reports data from multiple replicates (three independent experiments), satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, all three mutants (S935A, R1441G, and G2019S) exhibited reduced co-immunoprecipitation with Myc-14-3-3c... binding of 14-3-3 to mutant R1441G or Y1699C is markedly reduced.",
          "judgment": "Yes",
          "reasoning": "The study includes other known PD-linked variants (e.g., G2019S, R1441G) as controls alongside Y1699C, which are recognized as pathogenic in the field, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data was analyzed by One-way ANOVA (** P<0.01). Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) is performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood for functional data specific to Y1699C.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C... and G2019S... were tested for pS935 levels and 14-3-3 binding.",
          "judgment": "Less than 11 controls",
          "reasoning": "The study includes fewer than 11 total benign/pathogenic variant controls (only a few mutants like G2019S and R1441G are mentioned alongside wild-type), limiting the strength of evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 Y1699C is rated as PS3_supporting due to reduced phosphorylation at S935 and impaired 14-3-3 binding, consistent with a pathogenic role in PD. The strength is limited to supporting due to the small number of variant controls and absence of OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) have been linked to the most common familial form and some sporadic forms of Parkinson's disease (PD)... leading to the hypothesis of 'gain-of-function' in LRRK2 mutants with enhanced kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a 'gain-of-function' in LRRK2 mutants associated with PD, involving altered kinase and GTPase activities that contribute to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We examined the pS935 levels in the PD-linked mutants of LRRK2 expressed in HEK-293T cells... and 14-3-3 binding with LRRK2 variants in transfected cells.",
          "judgment": "Yes",
          "reasoning": "The assays used (phosphorylation level assessment via Western blot and protein binding via co-immunoprecipitation) are relevant to model the disease mechanism of altered kinase activity and protein interactions in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Compared to wild type LRRK2, mutant G2019S... showed a modest but significant decrease in pS935 levels... Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type LRRK2 as a normal control and reports data from multiple replicates (three independent experiments), satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, all three mutants (S935A, R1441G, and G2019S) exhibited reduced co-immunoprecipitation with Myc-14-3-3c... 14-3-3 binding is affected little in G2019S.",
          "judgment": "Yes",
          "reasoning": "The study includes other known PD-linked variants (e.g., R1441G, Y1699C) as controls alongside G2019S, which are recognized as pathogenic in the field, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data was analyzed by One-way ANOVA (** P<0.01). Data are presented as mean value (6 SEM) from three independent experiments.",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) is performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood for functional data specific to G2019S.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C... and G2019S... were tested for pS935 levels and 14-3-3 binding.",
          "judgment": "Less than 11 controls",
          "reasoning": "The study includes fewer than 11 total benign/pathogenic variant controls (only a few mutants like R1441G and Y1699C are mentioned alongside wild-type), limiting the strength of evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_supporting due to a modest reduction in pS935 levels and slight impairment in 14-3-3 binding, suggesting a pathogenic role in PD. The strength is limited to supporting due to the small number of variant controls and lack of OddsPath calculation."
    }
  ]
}